Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712033 | 0.96 | KMT2A (0.56) | SIGMAR1KMT2AMAOAMAOBBCHE | |
| SCHEMBL30104693 | 0.95 | RXFP1 (0.55) | SIGMAR1KMT2AMAOAMAOBBCHE | |
| SCHEMBL29711994 | 0.92 | SIGMAR1 (0.57) | SIGMAR1KMT2AMAOAMAOBBCHE | |
| SCHEMBL29712062 | 0.89 | KMT2A (0.54) | KMT2AMAOAMAOBPOLB | |
| SCHEMBL29640165 | 0.87 | POLB (0.57) | SIGMAR1KMT2AMAOAMAOBMEN1 | |
| SCHEMBL29640441 | 0.86 | SIGMAR1 (0.56) | SIGMAR1MAOAMAOBBCHEACHE | |
| SCHEMBL29640209 | 0.86 | RXFP1 (0.56) | SIGMAR1KMT2AMAOAMAOBBCHE | |
| SCHEMBL22966092 | 0.86 | POLB (0.50) | SIGMAR1KMT2AMAOAMAOBBCHE | |
| SCHEMBL29712052 | 0.86 | MAOA (0.51) | SIGMAR1KMT2AMAOAMAOBBCHE | |
| SCHEMBL24771759 | 0.84 | SIGMAR1 (0.56) | SIGMAR1MAOAMAOBBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4010341-A1 | TRKB POSITIVE ALLOSTERIC MODULATORS | Université de Strasbourg (FR) | 2022-06-15 | — | — | EP | disclosed |
| CN-114450006-A | TrkB positive allosteric modulators | 斯特拉斯堡大学 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | SIGMAR1 1243/4885KMT2A 850/4885MAOA 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.